GlassScriptPhysician profile
Gjorgii Trnovski
NPI 1245440668
$9,925.80
in general payments reported to CMS, 2019-2025
35 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $1,576 · 2021: $2,477 · 2022: $1,258 · 2023: $1,464 · 2024: $1,105 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,632.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,142.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,385.33 | 2021-2025 | Vraylar, Synthroid, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $929.10 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $896.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $683.01 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $638.95 | 2019-2022 | |
| Pfizer INC. | $496.56 | 2019-2025 | |
| Allergan, INC. | $387.47 | 2019-2020 | |
| Abbott Laboratories | $286.16 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $224.52 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $175.22 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $170.45 | 2022-2024 | Quviviq |
| Novo Nordisk INC | $149.45 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $129.98 | 2021-2025 | Trintellix |
| Tactile Systems Technology INC | $122.11 | 2024 | Flexitouch Plus, Entre Plus |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $112.58 | 2020-2025 | |
| Glaxosmithkline, LLC. | $107.67 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $102.15 | 2019-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $100.26 | 2020-2023 | |
| Mylan Specialty L.P. | $99.56 | 2020-2021 | |
| Lucid Diagnostics INC. | $92.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.85 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $69.20 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.88 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $59.23 | 2021-2024 | Camzyos |
| Astellas Pharma US INC | $50.21 | 2021 | |
| Tolmar, INC. | $32.47 | 2025 | Jatenzo |
| Biohaven Pharmaceutical Holding Company LTD. | $27.54 | 2022 | |
| Arbor Pharmaceuticals, INC. | $22.87 | 2021 | |
| Linus Health, INC. | $22.52 | 2022 | |
| Genzyme Corporation | $20.75 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.46 | 2020 | |
| Ibsa Pharma INC. | $15.47 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.91 | 2023 | Unithroid |
| Sanofi-Aventis U.S. LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gjorgii Trnovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.